ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 82

Variability of the SF-6D Determinants Over Time in Early Arthritis:Results From the Espoir Cohort

Cécile Gaujoux-Viala1, Bruno Fautrel2, Kossar Hosseini3, Francis Guillemin3, René-Marc Flipo4 and Anne-Christine Rat5, 1Lorraine University, Paris Descartes University, APEMAC, EA 4360, F- 54 000, Nancy; Paris 6 – Pierre et Marie Curie University; Rheumatology, Pitié-Salpêtrière Hospital, Paris, France, 2APHP, Pitié-Salpêtrière University Hospital, Paris, France, 3Lorraine University, Paris Descartes University, APEMAC, EA 4360, F- 54 000, Nancy, France, 4Rheumatology Department, Lille University Hospital, Lille, France, 5CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: quality of life and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease I

Session Type: Abstract Submissions (ACR)

 

Background/Purpose: There is growing emphasis on the cost-effectiveness of treating rheumatoid arthritis. The SF-6D, derived from the SF36, is an indirect utility measure widely used to calculate quality-adjusted life-years in order to assess health benefits. Few trials directly record the health utility measures (or the SF36), needed for economic analyses. Consequently linear regression methods have been used to transform Health Assessment Questionnaire (HAQ) scores into utility measures.

Objective: 1) To assess which variables are associated with the SF-6D in early arthritis over 3 years

2) To check if these associations are stable over 3 years

Methods: – Patients: Between 2002 and 2005, the ESPOIR cohort enrolled 813 patients with recent arthritis in at least 2 joints with 6 weeks to 6 months disease duration.

               – Data available: SF-6D utility measures were longitudinally assessed in 813 patients with EA (at baseline, 6 months, 1, 2 and 3 years). Clinical and biological variables and X-rays were also recorded.

               – Analysis:  The determinants of SF-6D-derived utility values at each time-point over 3 years were assessed by multivariate linear regressions to analyze which specific aspects of early arthritis were independently associated with the SF-6D.

Results: At baseline, higher HAQ, patient global evaluation, pain, fatigue, and lower mental status were significantly associated with lower SF-6D. HAQ and AIMS2-SF-mental scores explained 49 and 14% of the variance respectively. At 6 months, 1, 2 and 3 years, higher HAQ, patient global evaluation, fatigue, age and lower mental status were significantly associated with lower SF-6D. HAQ and AIMS2-SF-mental scores explained 7 to 13% and 55 to 57% of the variance respectively (figure).

Conclusion: The determinants of the SF-6D varied over 3 years in EA patients. At baseline, the SF-6D was essentially determined by function whereas after 6 months, the SF-6D was essentially determined by mental status. Cost-effectiveness models should not use utility values derived from HAQ.


Disclosure:

C. Gaujoux-Viala,
None;

B. Fautrel,
None;

K. Hosseini,
None;

F. Guillemin,
None;

R. M. Flipo,
None;

A. C. Rat,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/variability-of-the-sf-6d-determinants-over-time-in-early-arthritisresults-from-the-espoir-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology